<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="brief-report" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">789074</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2021.789074</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Brief Research Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Anti-Inflammatory and Anti-Oxidative Effects of AM404 in IL-1&#x3b2;-Stimulated SK-N-SH Neuroblastoma Cells</article-title>
<alt-title alt-title-type="left-running-head">Apweiler et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Anti-Inflammatory and Anti-Oxidative Effects of AM404</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Apweiler</surname>
<given-names>Matthias</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1505930/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Streyczek</surname>
<given-names>Jana</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1516491/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Saliba</surname>
<given-names>Soraya Wilke</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/577057/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ditrich</surname>
<given-names>Johannes</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mu&#x00F1;oz</surname>
<given-names>Eduardo</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/620246/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fiebich</surname>
<given-names>Bernd L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/20275/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Neuroimmunology and Neurochemistry Research Group, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, <addr-line>Freiburg</addr-line>, <country>Germany</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Zentrum f&#xfc;r Psychiatrie Emmendingen, <addr-line>Emmendingen</addr-line>, <country>Germany</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Departamento de Biolog&#xed;a Celular, Fisiolog&#xed;a e Inmunolog&#xed;a, Universidad de C&#xf3;rdoba, <addr-line>C&#xf3;rdoba</addr-line>, <country>Spain</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Instituto Maim&#xf3;nides de Investigaci&#xf3;n Biom&#xe9;dica de C&#xf3;rdoba, <addr-line>C&#xf3;rdoba</addr-line>, <country>Spain</country>
</aff>
<aff id="aff5">
<label>
<sup>5</sup>
</label>Hospital Universitario Reina Sof&#xed;a, <addr-line>C&#xf3;rdoba</addr-line>, <country>Spain</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/13609/overview">Emanuela Ricciotti</ext-link>, University of Pennsylvania, United&#x20;States</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/183162/overview">Paolo Tucci</ext-link>, University of Foggia, Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/157960/overview">Santiago J.&#x20;Ballaz</ext-link>, Yachay Tech University, Ecuador</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Bernd L. Fiebich, <email>bernd.fiebich@uniklinik-freiburg.de</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors share first authorship</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>789074</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>10</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>01</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Apweiler, Streyczek, Saliba, Ditrich, Mu&#x00F1;oz and Fiebich.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Apweiler, Streyczek, Saliba, Ditrich, Mu&#x00F1;oz and Fiebich</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>An emerging number of studies address the involvement of neuroinflammation and oxidative stress in the pathophysiology of central nervous system (CNS) disorders such as depression, schizophrenia, anxiety, and neurodegenerative diseases. Different cytokines and molecules, such as prostaglandin (PG) E<sub>2</sub>, are associated with neuroinflammatory processes. The active acetaminophen metabolite AM404 has been shown to prevent inflammation and neuroinflammation in primary microglia and organotypic hippocampal slice cultures. However, its effects on pathophysiological conditions in the CNS and especially on neurons are still poorly understood. In this study, we therefore evaluated the effects of AM404 and acetaminophen on the arachidonic acid cascade and oxidative stress induced by interleukin (IL)-1&#x3b2; in human SK-N-SH neuronal cells. We observed that AM404 and acetaminophen significantly and concentration-dependent inhibited IL-1&#x3b2;-induced release of PGE<sub>2</sub>, independent of cyclooxygenases (COX)-1 and COX-2 enzymatic activity as well as COX-2 mRNA and protein levels in SK-N-SH-cells. The reduction of IL-1&#x3b2;-induced PGE<sub>2</sub>-release by AM404 and acetaminophen treatment might be mediated by the 8-iso-PGF<sub>2&#x3b1;</sub> pathway since IL-1&#x3b2;-induced synthesis of this free radical marker is dose-dependently reduced by both compounds, respectively. Therefore, understanding of the potential therapeutic properties of AM404 in neuroinflammation and oxidative stress might lead to future treatment options of different neurological disorders.</p>
</abstract>
<kwd-group>
<kwd>AM404</kwd>
<kwd>paracetamol</kwd>
<kwd>acetaminophen</kwd>
<kwd>prostaglandin E<sub>2</sub>
</kwd>
<kwd>8-iso-PGF<sub>2&#x3b1;</sub>
</kwd>
<kwd>cyclooxygenase</kwd>
<kwd>neuroinflammation</kwd>
<kwd>oxidative stress</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Neurodegeneration is an important characteristic of different diseases such as Alzheimer&#x2019;s Disease (AD), Parkinson&#x2019;s Disease (PD), and other neuropsychiatric diseases (<xref ref-type="bibr" rid="B45">Sultana et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B21">Joshi and Pratic&#xf2;, 2014</xref>). On the molecular level, different pathomechanisms may induce neurodegeneration such as wrong-folded proteins accumulating in the brain, neuroinflammation, and oxidative stress (<xref ref-type="bibr" rid="B10">Brundin et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B37">Rozp&#x119;dek-Kami&#x144;ska et&#x20;al., 2020</xref>), with the two latter being closely connected and promoting each other (<xref ref-type="bibr" rid="B35">Picca et&#x20;al., 2020</xref>). Psychiatric disorders, as for example depression, schizophrenia, and anxiety disorders, are also associated with neuroinflammation and oxidative stress (<xref ref-type="bibr" rid="B40">Salim, 2014</xref>).</p>
<p>Besides neuroinflammation, oxidative stress is associated with neuronal damage and neuropsychiatric diseases (<xref ref-type="bibr" rid="B45">Sultana et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B21">Joshi and Pratic&#xf2;, 2014</xref>). An example is the production of 8-iso-prostaglandin (PG) F<sub>2&#x3b1;</sub> induced by amyloid beta in &#x3b2;-pleated sheet conformations, as part of senile plaques in AD (<xref ref-type="bibr" rid="B27">Mark et&#x20;al., 2008</xref>). Since the CNS is highly metabolic active, reactive oxygen species (ROS) arising of this metabolism need to be cleared to maintain oxidative homeostasis (<xref ref-type="bibr" rid="B42">Singh et&#x20;al., 2019</xref>). Under normal conditions, ROS are neutralized by antioxidants and enzymatic cell processes. If these mechanisms are exhausted, concentrations of ROS rise, damaging parts of the cell, such as proteins, membranes, and lipids, (<xref ref-type="bibr" rid="B21">Joshi and Pratic&#xf2;, 2014</xref>). Lipid peroxidation is a consequence of high intracellular ROS-levels resulting in highly reactive aldehydes or cyclized fatty acid esters such as isoprostanes (<xref ref-type="bibr" rid="B45">Sultana et&#x20;al., 2013</xref>). 8-iso-PGF<sub>2&#x3b1;</sub>, also known as 8-isoprostane, is described as sensitive marker for detecting oxidative stress in cells and is associated with cytotoxicity in higher concentrations (<xref ref-type="bibr" rid="B27">Mark et&#x20;al., 2008</xref>). It is formed by lipid peroxidation of arachidonic acid (AA) independent of cyclooxygenases (COXs). In addition to its direct cytotoxic and pro-oxidative effects, 8-iso-PGF<sub>2&#x3b1;</sub> might potentially act as a signaling molecule by binding to a modified form of isoprostane receptors activating mitogen activated protein kinase (MAPK)-pathways (<xref ref-type="bibr" rid="B1">Acquaviva et&#x20;al., 2013</xref>). Yet, downstream signaling of isoprostanes and possible involvement in the COX-2/PGE<sub>2</sub> pathway is still poorly understood.</p>
<p>Since acetaminophen, also known as paracetamol, has been introduced to the pharmaceutical market, it has quickly gained importance. It is known to reduce pain and fever, but its molecular mechanisms, besides its effects on prostaglandins, are not fully understood so far. <italic>N</italic>-arachidonoylphenolamine (AM404) is a metabolite of acetaminophen. In the CNS, acetaminophen is deacetylated to phospho-acetaminophen and conjugated with AA by the fatty acid amide hydrolase (FAAH) to form AM404 (<xref ref-type="bibr" rid="B19">H&#xf6;gest&#xe4;tt et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B6">Bertolini et&#x20;al., 2006</xref>). Acetaminophen is used as an analgetic and antipyretic drug through inhibition of PG-synthesis but is not suggested to be a potent anti-inflammatory drug (<xref ref-type="bibr" rid="B17">Flower and Vane, 1972</xref>). AM404 is discussed as the active metabolite of acetaminophen responsible for its central effects by acting <italic>via</italic> cannabinoid receptor 1 (CB1) or transient receptor potential vanilloid receptor 1 (TRPV1) (<xref ref-type="bibr" rid="B51">Zygmunt et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B6">Bertolini et&#x20;al., 2006</xref>). The endocannabinoid system, including CB1 and CB2 receptors and their endogenous as well as exogenous ligands, is an important system and target for the regulation of inflammatory processes (<xref ref-type="bibr" rid="B33">Pacher et&#x20;al., 2006</xref>).</p>
<p>AM404 has been demonstrated to reduce inflammation and oxidative stress. AM404 reduced cluster of differentiation (CD)3/CD28-induced interleukin (IL)-2 release and T-cell proliferation in Jurkat cells, inhibiting NFAT-transcription and transcriptional factor activity (<xref ref-type="bibr" rid="B11">Caballero et&#x20;al., 2007</xref>). The treatment of Sprague Dawley rats with AM404 ameliorated lipopolysaccharide (LPS)-induced IL-1&#x3b2;- and IL-6-levels and increased tumor necrosis factor alpha (TNF&#x3b1;) concentrations in the plasma (<xref ref-type="bibr" rid="B36">Roche et&#x20;al., 2008</xref>). In murine 4-aminopyridine-induced epileptic hippocampal neurons, AM404 reduced anandamide- and capsaicin-induced Ca<sup>2&#x2b;</sup>-accumulation, apoptosis and ROS-generation (<xref ref-type="bibr" rid="B31">Naz&#x131;ro&#x11f;lu et&#x20;al., 2019</xref>). In our previous studies, we showed the reduction of LPS-induced PGE<sub>2</sub> and 8-isoprostane release by AM404 in concentration-dependent manner in primary rat microglia (<xref ref-type="bibr" rid="B39">Saliba et&#x20;al., 2017</xref>) and N-methyl-D-aspartate (NMDA)-induced IL-1&#x3b2;-expression in organotypic hippocampal slice cultures (OHSC) of mouse brain (<xref ref-type="bibr" rid="B38">Saliba et&#x20;al., 2019</xref>). Furthermore, COX-2 protein levels and COX-activity induced by LPS were significantly reduced by AM404. The observed anti-inflammatory effects were independent of TRPV1, as shown using microglia from TRPV1 knockout mice (<xref ref-type="bibr" rid="B39">Saliba et&#x20;al., 2017</xref>). Microglia are known to be key effectors in neuroinflammation and in inflammatory response to external stressors (<xref ref-type="bibr" rid="B49">Yap et&#x20;al., 2019</xref>). Their response is not only affecting themselves and other immune cells of the CNS, but also triggering inflammatory processes and responses in neurons leading to neurodegenerative, neuropsychiatric, and cognitive symptoms (<xref ref-type="bibr" rid="B30">Najjar et&#x20;al., 2013</xref>; <xref ref-type="bibr" rid="B49">Yap et&#x20;al., 2019</xref>). Neuroinflammation can be described as an imbalance between anti-inflammatory and pro-inflammatory mediators due to internal or external stimuli (<xref ref-type="bibr" rid="B13">Craft et&#x20;al., 2005</xref>). Neuroinflammatory molecules released by microglia and neurons are for instance IL-1&#x3b2;, IL-6, and PGE<sub>2</sub> (<xref ref-type="bibr" rid="B13">Craft et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B26">Lima et&#x20;al., 2012</xref>), the latter is synthesized from AA by enzymatic activity of COX-1/2 and microsomal prostaglandin synthase (mPGES)-1 (<xref ref-type="bibr" rid="B24">Lee et&#x20;al., 2010</xref>).</p>
<p>Neuroprotective effects of AM404 have been also reported <italic>ex vivo</italic> and <italic>in vivo</italic>. In OHSC, AM404 protects against NMDA-induced neurotoxicity (<xref ref-type="bibr" rid="B38">Saliba et&#x20;al., 2019</xref>). In 3xTg-AD mice, systemic low dose treatment with AM404 reduced memory impairment and loss of serotonergic and noradrenergic neurons. Furthermore, serum levels of IL-6 and TNF&#x3b1; were significantly decreased by AM404 treatment. Concentrations used for the treatment of mice were beneath reported minimal concentrations for CB1 and TRPV1 receptor activation. Therefore, the effects shown might be receptor-independent and might be mediated by nonspecific targets, such as anti-oxidative pathways (<xref ref-type="bibr" rid="B20">Huang et&#x20;al., 2019</xref>). Other studies found anxiolytic and antidepressant effects of AM404 in animal models (<xref ref-type="bibr" rid="B7">Bortolato et&#x20;al., 2006</xref>; <xref ref-type="bibr" rid="B34">Patel and Hillard, 2006</xref>; <xref ref-type="bibr" rid="B2">Adamczyk et&#x20;al., 2008</xref>) as well as neuroprotective effects in a rat model of PD (<xref ref-type="bibr" rid="B14">Fernandez-Espejo et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B18">Garc&#xed;a-Arencibia et&#x20;al., 2007</xref>). With a more detailed understanding of its molecular mechanisms and effects, AM404 might be an interesting option in the treatment of neurological and psychiatric diseases associated with neuroinflammatory or oxidative processes.</p>
<p>The current study focuses on the effects of AM404 and acetaminophen in human SK-N-SH neuroblastoma cells by evaluating IL-1&#x3b2;-induced neuroinflammatory and oxidative endpoints, such as PGE<sub>2</sub>-and 8-iso-PGF<sub>2&#x3b1;</sub>-concentrations, and the underlying mechanisms.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec id="s2-1">
<title>Chemicals</title>
<p>N-arachidonoylphenolamine (AM404; Alomone Labs, Jerusalem, Israel) was dissolved in DMSO (Merck KGaA, Darmstadt, Germany) and used in final concentrations of 0.1&#x2013;10&#xa0;&#xb5;M. Acetaminophen (APAP; paracetamol; Sigma-Aldrich GmbH, Taufkirchen, Germany) was dissolved in ethanol (Sigma-Aldrich) and used in final concentrations of 1&#x2013;50&#xa0;&#xb5;M. The chosen range of AM404 (<xref ref-type="bibr" rid="B39">Saliba et&#x20;al., 2017</xref>) and acetaminophen (<xref ref-type="bibr" rid="B16">Fiebich et&#x20;al., 2000</xref>) concentrations was based on previous studies. To compare CB1- and CB2-mediated effects on PGE<sub>2</sub>-release, arachidonyl-2&#x2032;-chloroethylamide (ACEA, CB1 agonist; in ethanol, Biotrend Chemicals AG, K&#xf6;ln, Germany) and (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015; CB2 agonist, in DMSO; Tocris Bioscience, Bristol, United&#x20;Kingdom) were used. Human IL-1&#x3b2; [100,000&#xa0;U/ml in phosphate buffered saline (PBS)] was purchased from Roche Diagnostics (Manheim, Germany) and used at a final concentration of 10&#xa0;U/ml in the experiments.</p>
</sec>
<sec id="s2-2">
<title>Human Neuroblastoma (SK-N-SH) Cell Culture</title>
<p>SK-N-SH-cells were obtained from the ATCC (HTB-11, Rockville, United&#x20;States) and grown in 1&#xd7; minimum essential medium (MEM) containing Earl&#x2019;s salts, 10% fetal bovine serum (Bio &#x26; SELL GmbH, Feucht/N&#xfc;rnberg, Germany), 1&#xa0;mM l-glutamine, 1&#xa0;mM sodium pyruvate, 2&#xa0;ml of 100x MEM vitamin solution, 40&#xa0;units/ml penicillin, 40&#xa0;&#x3bc;g/ml streptomycin, and 0.1&#xa0;&#x3bc;g/ml fungizone<sup>&#xae;</sup> (all obtained from Gibco, Thermo Fisher Scientific, Bonn, Germany). Cells were incubated at 37&#xb0;C in a humidified atmosphere with 5% CO<sub>2</sub>. Confluent monolayers were passaged routinely by trypsinization. After trypsinization, cells were harvested and re-seeded into 6-, 12-, 24-, or 96-well plates. On the next day, medium was changed and after 1&#xa0;h, cells were stimulated for respective experiments.</p>
</sec>
<sec id="s2-3">
<title>Cell Viability Assay</title>
<p>Viability of SK-N-SH-cells after treatment with AM404 and acetaminophen was measured using MTT assay (Sigma-Aldrich). This assay determines the number of metabolically active and viable cells in cell culture based on the reduction of a yellow tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT] to purple formazan. Briefly, cells were cultured in 96-well plates at the density of 25&#x20;&#xd7; 10<sup>3</sup> cells/well for 24&#xa0;h. Then, medium was changed and after at least 1&#xa0;h, cells were pre-treated with different concentrations of AM404 or acetaminophen for 30&#xa0;min. Cells were then incubated with or without IL-1&#x3b2; for the next 20&#xa0;h. Ethanol (20% end conc.) was used as positive control to induce cell death. Next, 20&#xa0;&#xb5;l of MTT-solution (5&#xa0;mg/ml) were added to all wells and incubated for another 4&#xa0;h at 37&#xb0;C. Then, medium was removed and 200&#xa0;&#xb5;l of DMSO were added. Colorimetric reaction was measured using MRX<sup>e</sup> Microplate reader (Dynex Technologies, Denkerdorf, Germany) at 595&#xa0;nm.</p>
</sec>
<sec id="s2-4">
<title>Determination of PGE<sub>2</sub>-and 8-Iso-PGF<sub>2&#x3b1;</sub> (8-Isoprostane)-Release</title>
<p>SK-N-SH-cells were pre-treated with AM404 (0.1&#x2013;10&#xa0;&#xb5;M), acetaminophen (0.1&#x2013;50&#xa0;&#xb5;M), ACEA (0.1&#x2013;10&#xa0;&#xb5;M), or JWH-015 (0.1&#x2013;10&#xa0;&#xb5;M) for 30&#xa0;min. Afterwards, cells were incubated with or without IL-1&#x3b2; (10&#xa0;U/ml) for the next 24&#xa0;h and supernatants were collected. The levels of PGE<sub>2</sub> and 8-iso-PGF<sub>2&#x3b1;</sub> were measured using commercially available enzyme immunoassay (EIA) kits (Cayman Chemicals, Ann Arbor, Michigan, United&#x20;States, distributed by BioMol, Hamburg, Germany) following the manufacturer&#x2019;s protocol. The results were normalized to IL-1&#x3b2; and presented as percentage of change in PG-levels of at least three independent experiments.</p>
</sec>
<sec id="s2-5">
<title>Cyclooxygenase Activity Assay</title>
<p>The COX enzymatic activity was investigated using the AA assay (<xref ref-type="bibr" rid="B15">Fiebich and Chrubasik, 2004</xref>). For COX-1 activity, neuroblastoma cells were plated in 24-well plates and after 24&#xa0;h, medium was removed and replaced with serum-free medium. AM404 (0.1&#x2013;10&#xa0;&#xb5;M) or selective inhibitors of COX-1 [acetylsalicylic acid (ASA, 10&#xa0;&#x3bc;M), and SC560 (1&#xa0;&#x3bc;M); Sigma-Aldrich] were added, and left for 15&#xa0;min. Then, AA (15&#xa0;&#x3bc;M; Sigma-Aldrich) was applied for another 15&#xa0;min. Finally, supernatants were collected and used for the determination of&#x20;PGE<sub>2</sub>.</p>
<p>For COX-2 enzymatic activity, the assay was conducted as described for COX-1, but with pre-incubation of IL-1&#x3b2; (10&#xa0;U/ml) for 24&#xa0;h to induce COX-2 synthesis and using diclofenac (1&#xa0;&#x3bc;M; Sigma-Aldrich) as preferential COX-2 inhibitor.</p>
</sec>
<sec id="s2-6">
<title>Immunoblotting</title>
<p>SK-N-SH-cells were pre-treated with AM404 (0.1&#x2013;10&#xa0;&#xb5;M) for 30&#xa0;min. After 24&#xa0;h of IL-1&#x3b2;-stimulation (10&#xa0;U/ml), cells were washed with cold PBS and lysed mechanically in lysis buffer (42&#xa0;mM Tris&#x2013;HCl, 1.3% sodium dodecyl sulfate, 6.5% glycerin, 100&#xa0;&#x3bc;M sodium orthovanadate, and 2% phosphatase and 0.2% protease inhibitors). Protein concentrations of the samples were measured using the bicinchoninic acid protein assay kit (Thermo Fisher Scientific). For Western blotting, 20&#xa0;&#x3bc;g of total protein from each sample were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. Proteins were then transferred onto polyvinylidene fluoride membranes (Merck Millipore) by semi-dry blotting. After blocking with Roti-Block (Roth, Karlsruhe, Germany), membranes were incubated overnight with primary antibody [mouse anti-COX-2 (MAB-4198, 1:1000; RD systems, Wiesbaden, Germany). The proteins were detected with horseradish peroxidase-coupled sheep anti-mouse IgG (1:20,000 dilution; Amersham Biosciences GmbH, Freiburg, Germany) using enhanced chemiluminescence (ECL) reagents (Biozym, Hessisch Oldendorf, Germany). Densitometric analysis was performed using ImageJ software (NIH, United&#x20;States).</p>
</sec>
<sec id="s2-7">
<title>RNA Isolation and Quantitative PCR</title>
<p>For quantification of the mRNA of the enzymes of the COX-2/PGE<sub>2</sub> pathway, we performed quantitative real-time PCR (qPCR) in SK-N-SH-cells. Cultured cells were pre-treated with AM404 (0.1&#x2013;10&#xa0;&#xb5;M) for 30&#xa0;min, followed by stimulation with IL-1&#x3b2; (10&#xa0;U/ml) for 4&#xa0;h. Total RNA was extracted using the GeneMATRIX Universal RNA Purification Kit (Roboklon GmbH, Berlin, Deutschland), according to the manufacturer&#x2019;s protocol. Then, cDNA was reverse transcribed from 500&#xa0;ng of total RNA with initial denaturation at 70&#xb0;C followed by amplification cycle after addition of master mix. qPCR amplification was carried out by the CFX96 real-time PCR detection system (Bio-Rad Laboratories GmbH, Feldkirchen, Germany). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as an internal control for sample normalization. The primer sequences were GAPDH: Fwd: 5&#x2032;-TGGGAAGCTGGTCATCAAC-3&#x2032;/Rev: 5&#x2032;- GCA&#x200b;TCA&#x200b;CCC&#x200b;CAT&#x200b;TTG&#x200b;ATG&#x200b;TT-3&#x2032;, COX-2: Fwd: 5&#x2032;- CTTCACGCATTTCAAG -3&#x2032;/Rev: 5&#x2032;- TCACCGTAAAGTCCAC -3&#x2032; and mPGES-1: Fwd 5&#x2032;-TGCAGCACGCTGCTGGTCAT-3&#x2032;/Rev 5&#x2032;-GTC&#x200b;GTT&#x200b;GCG&#x200b;GTG&#x200b;GGC&#x200b;TCT&#x200b;GAG-3&#x2032;. Primers were designed using Universal ProbeLibrary Assay Design Center (Roche Diagnostics) and obtained by <ext-link ext-link-type="uri" xlink:href="http://biomers.net">biomers.net</ext-link> GmbH (Ulm, Germany).</p>
</sec>
<sec id="s2-8">
<title>ORAC-Assay</title>
<p>The anti-oxidative capacity of AM404 (10 and 25&#xa0;&#xb5;M) was evaluated using the OxiSelect&#x2122; oxygen radical antioxidant capacity (ORAC) <italic>ex vivo</italic> activity assay (Cell Biolabs, Inc., San Diego, CA, United&#x20;States) following the manufacturer&#x2019;s instructions. Briefly, Trolox&#x2122; antioxidant standard or test samples were added to a 96-well plate, mixed with fluorescein solution and after 30&#xa0;min incubation at 37&#xb0;C, free radical initiator solution was added to all wells. Fluorescence was determined at 37&#xb0;C using a microplate reader (PerkinElmer Victor X5 2030-0050 Multimode Plate Reader, Rodgau, Germany; excitation wavelength 485&#xa0;nm, emission wavelength 535&#xa0;nm). Raw values were transformed to Trolox Equivalents&#x20;(TE).</p>
</sec>
<sec id="s2-9">
<title>Statistical Analysis</title>
<p>Raw values were converted to percentage and IL-1&#x3b2; (10&#xa0;U/ml) or the appropriate positive control, such as untreated cells for MTT-assay, were considered as 100%. Data are represented as mean&#x20;&#xb1; SEM of at least three independent experiments. The statistical comparisons were performed using one-way ANOVA with Dunett&#x2019;s post hoc test (Prism 8 software, GraphPad software Inc., San Diego, CA, United&#x20;States). The level of significance was set at &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 and &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Effects of AM404 and Acetaminophen on Cell Viability</title>
<p>We first evaluated the effects of AM404 and acetaminophen on cell viability of SK-N-SH-cells. As shown in <xref ref-type="fig" rid="F1">Figure&#x20;1</xref>, neither AM404 (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>) nor acetaminophen (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>), significantly reduced cell viability in the used concentrations with or without IL-1&#x3b2;-treatment compared to unstimulated cells, whereas 20% ethanol significantly induced cell death. DMSO and ethanol as solvents of AM404 and acetaminophen, respectively, did not affect cell viability in the concentrations used for the experiments.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Effects of AM404&#x20;<bold>(A,C)</bold> and acetaminophen <bold>(B,D)</bold> on cell viability <bold>(A,B)</bold> and PGE<sub>2</sub> release <bold>(C,D)</bold> of IL-1&#x3b2;-stimulated SK-N-SH-cells (24&#xa0;h treatment). Cells were stimulated as described under material and methods. <bold>(A,B)</bold> Cell viability was measured by change in color due to MTT-oxidation and absorbance was measured at 595&#xa0;nm using an ELISA-reader. <bold>(C,D)</bold> After 24&#xa0;h of stimulation, supernatants were collected and release of PGE<sub>2</sub> was measured by EIA. Values are presented as the mean&#x20;&#xb1; SEM of at least three independent experiments. Statistical analysis was performed using one-way ANOVA with Dunett&#x2019;s post hoc test with &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 and &#x23;&#x23;&#x23;&#x23;/&#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001 compared to untreated cells <bold>(A,B)</bold> or IL-1&#x3b2; <bold>(C,D)</bold>.</p>
</caption>
<graphic xlink:href="fphar-12-789074-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Effects of AM404 and Acetaminophen on IL-1&#x3b2;-Induced PGE<sub>2</sub>-Release</title>
<p>We next evaluated the effects of non-toxic doses of AM404 and acetaminophen on IL-1&#x3b2;-induced PGE<sub>2</sub>-release in human SK-N-SH neuroblastoma cells. As shown in <xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>, IL-1&#x3b2; potently induced an increase of PGE<sub>2</sub>-release compared to the untreated control and this effect was, in a concentration-dependent manner, significantly inhibited by all concentrations of AM404 (0.1&#x2013;10&#xa0;&#xb5;M). Acetaminophen (1&#x2013;50&#xa0;&#xb5;M) also showed significant and concentration-dependent inhibitory effects on IL-1&#x3b2;-stimulated PGE<sub>2</sub>-release (<xref ref-type="fig" rid="F1">Figure&#x20;1D</xref>).</p>
<p>ACEA, a CB1 agonist, significantly increased IL-1&#x3b2;-induced PGE<sub>2</sub>-release, whereas JWH-015, a CB2 agonist, weakly reduced IL-1&#x3b2;-mediated PGE<sub>2</sub>-synthesis by approximately maximal 50% in SK-N-SH-cells (<xref ref-type="sec" rid="s11">Supplementary Figure S1</xref>). Both CB receptors are expressed in SK-N-SH-cells (data not shown).</p>
</sec>
<sec id="s3-3">
<title>Effects of AM404 on COX-1 and -2 Expression and COX-2 Protein Levels</title>
<p>There are two known COX enzymes; COX-1 is constitutively expressed in most tissues, whereas COX-2 is mainly induced by inflammatory stimuli but also constitutively expressed in some cells (<xref ref-type="bibr" rid="B53">Samuelsson et&#x20;al., 1975</xref>; <xref ref-type="bibr" rid="B54">Sigal, 1991</xref>). Most PGs are synthesized during inflammation by COX-2 and mPGES-1 enzymes (<xref ref-type="bibr" rid="B52">Kudo and Murakami, 2005</xref>). We evaluated effects of AM404 on COX-2 protein levels and COX-1, COX-2, and mPGES-1 mRNA expression. As shown in <xref ref-type="fig" rid="F2">Figure&#x20;2</xref>, IL-1&#x3b2; potently induced COX-2 protein synthesis and COX-2 and mPGES-1 mRNA expression. COX-2 protein levels were not affected by AM404 treatment (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>), while mRNA-expression was slightly but still significantly enhanced in concentrations of 10&#xa0;&#xb5;M (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). The expression of mPGES-1 was marginally but still significantly increased in the concentrations of 1&#xa0;&#xb5;M AM404 (<xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>). COX-1 mRNA-expression (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>) was decreased by IL-1&#x3b2; compared to untreated cells. AM404 did not reverse IL-1&#x3b2;-induced reduction of COX-1&#x20;mRNA.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Effects of AM404 on COX-2 protein levels <bold>(A)</bold>, COX-2 expression <bold>(B)</bold>, mPGES-1 expression <bold>(C)</bold>, and COX-1 expression <bold>(D)</bold> in IL-1&#x3b2;-stimulated SK-N-SH-cells. Cells were stimulated as described under material and methods. After 4&#xa0;h of stimulation, RNA was isolated and mRNA levels of the shown target genes were measured in qPCR. Values are presented as the mean&#x20;&#xb1; SEM of at least three independent experiments. Statistical analysis was performed using one-way ANOVA with Dunnett&#x2019;s post hoc tests with &#x2a;/&#x23;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;/&#x23;&#x23;<italic>p</italic>&#x20;&#x3c; 0.01 compared to IL-1&#x3b2; <bold>(A&#x2013;C)</bold> or to untreated cells <bold>(D)</bold>.</p>
</caption>
<graphic xlink:href="fphar-12-789074-g002.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>Effects of AM404 on COX Activity</title>
<p>Since PGE<sub>2</sub>-levels induced by IL-1&#x3b2; are inhibited by AM404 treatment, we investigated whether AM404 directly affected COX enzymatic activity as shown for most non-steroidal anti-inflammatory drugs such as acetyl salicylic acid (ASA), diclofenac, ibuoprofen, and many others. We observed that AM404 did not affect COX-1 activity (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>) and partially but not significantly (&#xb1;40%) inhibited COX-2 activity in the doses of 5 and 10&#xa0;&#xb5;M (<xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>). Known inhibitors of COX-1 (SC560, ASA) and COX-2, (diclofenac) showed a prominent reduction of COX-1 or COX-2 activity. Acetaminophen does not affect COX-activities as shown in multiple studies before (<xref ref-type="bibr" rid="B32">Ohashi and Kohno, 2020</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Effects of AM404 on COX-1 enzyme activity <bold>(A)</bold> and COX-2 enzyme activity <bold>(B)</bold> in SK-N-SH-cells. <bold>(A)</bold> COX-1-activity was measured after 15&#xa0;min of incubation with arachidonic acid (AA). Levels of PGE<sub>2</sub> in the supernatants were quantified by EIA. <bold>(B)</bold> After 24&#xa0;h IL-1&#x3b2;-pre-stimulation, 15&#xa0;&#xb5;M of AA was added and PGE<sub>2</sub>-release was measured by EIA. Values are presented as the mean&#x20;&#xb1; SEM of at least three independent experiments. Statistical analysis was carried out by using one-way ANOVA with Dunnett&#x2019;s post hoc tests with &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001 compared to AA <bold>(A)</bold> or IL-1&#x3b2; with AA <bold>(B)</bold>.</p>
</caption>
<graphic xlink:href="fphar-12-789074-g003.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>Effects of AM404 on Oxidative Stress and as Anti-Oxidative Molecule</title>
<p>Since the reduction of IL-1&#x3b2;-induced PGE<sub>2</sub>-levels after treatment with AM404 cannot be explained by changes in COX-expression nor enzyme synthesis or activity, we investigated anti-oxidative mechanisms underlying the PGE<sub>2</sub>-reduction. Therefore, we evaluated the effects of AM404 and acetaminophen on IL-1&#x3b2;-induced 8-Iso-PGF<sub>2&#x3b1;</sub>-release in SK-N-SH-cells. The effects of AM404 and acetaminophen on IL-1&#x3b2;-induced 8-iso-PGF<sub>2&#x3b1;</sub>-release are shown in <xref ref-type="fig" rid="F4">Figure&#x20;4</xref>. IL-1&#x3b2; stimulation strongly induced the release of 8-iso-PGF<sub>2&#x3b1;</sub> compared to untreated cells. AM404 (<xref ref-type="fig" rid="F4">Figure&#x20;4A</xref>) as well as acetaminophen (<xref ref-type="fig" rid="F4">Figure&#x20;4B</xref>) reduced IL-1&#x3b2;-mediated 8-iso-PGF<sub>2&#x3b1;</sub>-release in a concentration dependent manner. A significant reduction of IL-1&#x3b2;-induced 8-iso-PGF<sub>2&#x3b1;</sub> was observed in the concentrations of 10&#xa0;&#xb5;M of AM404 and starting with 1&#xa0;&#xb5;M of acetaminophen to levels close to untreated cells using the dose of 50&#xa0;&#xb5;M.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Effects of AM404&#x20;<bold>(A)</bold> and acetaminophen <bold>(B)</bold> on 8-iso-PGF<sub>2&#x3b1;</sub>-release in IL-1&#x3b2;-stimulated SK-N-SH-cells. Cells were stimulated as described under material and methods. After 24&#xa0;h of stimulation, supernatants were collected and release of 8-iso-PGF<sub>2&#x3b1;</sub> was measured by EIA. Values are presented as the mean&#x20;&#xb1; SEM of at least three independent experiments. Statistical analysis was performed using one-way ANOVA with Dunnett&#x2019;s post hoc tests with &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001, &#x2a;&#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.0001 compared to IL-1&#x3b2;.</p>
</caption>
<graphic xlink:href="fphar-12-789074-g004.tif"/>
</fig>
<p>The anti-oxidative capacity of AM404 was determined in comparison to Trolox. AM404 showed around half of the anti-oxidative capacity of the vitamin E analog Trolox, with 6.8&#xa0;&#xb5;M of Trolox being as effective as 10&#xa0;&#xb5;M AM404 and 13.2&#xa0;&#xb5;M of Trolox being as effective as 25&#xa0;&#xb5;M AM404.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>The current study demonstrates that acetaminophen and its active metabolite AM404 significantly and concentration-dependently reduced the release of IL-1&#x3b2;-induced PGE<sub>2</sub>. The PGE<sub>2</sub> inhibiting effects of AM404 are independent of COX-1 and COX-2 enzymatic activity. In addition, the observed AM404 effects on PGE<sub>2</sub>-levels are also independent of COX-2 protein as well as COX-2 and mPGES-1 mRNA levels. We demonstrate here that IL-1&#x3b2;-induced 8-iso-PGF<sub>2&#x3b1;</sub>-release [a reliable and highly sensitive marker to assess oxidative stress (<xref ref-type="bibr" rid="B27">Mark et&#x20;al., 2008</xref>)] was significantly decreased by acetaminophen and AM404, and therefore might participate in the decrease of PGE<sub>2</sub>-synthesis.</p>
<p>As shown in our previous study (<xref ref-type="bibr" rid="B39">Saliba et&#x20;al., 2017</xref>), AM404 prevented the synthesis of PGE<sub>2</sub> and 8-iso-PGF<sub>2&#x3b1;</sub> in LPS-stimulated primary rat microglia independent of its suggested target receptors CB1 and TRPV1. In primary rat microglia, we found slightly decreased COX-2 and no effect on mPGES-1 protein levels. Furthermore, AM404 reduced COX-1 and COX-2 enzymatic activity, contributing to the observed inhibitory effects on the prostaglandins.</p>
<p>Activated microglia are understood as inflammation driving cells in the CNS, with neurons contributing to inflammation in smaller ways but being especially affected by inflammatory processes (<xref ref-type="bibr" rid="B49">Yap et&#x20;al., 2019</xref>). Therefore, we evaluated the role of AM404 on the neuroinflammatory COX-2/PGE<sub>2</sub> pathway in human SK-N-SH neuroblastoma cells to replenish the previous microglial results with neuronal cell experiments. In contrast to our microglial results, AM404 reduced IL-1&#x3b2;-induced PGE<sub>2</sub>-and 8-iso-PGF<sub>2&#x3b1;</sub>-release in SK-N-SH-cells, independent of COX enzymatic activity, protein, and mRNA levels.</p>
<p>Oxidative stress is closely connected to neuroinflammation with both conditions promoting each other (<xref ref-type="bibr" rid="B43">Solleiro-Villavicencio and Rivas-Arancibia, 2018</xref>; <xref ref-type="bibr" rid="B35">Picca et&#x20;al., 2020</xref>), and the modulation of oxidative stress by anti-oxidative compounds has been reported to decrease neuroinflammation (<xref ref-type="bibr" rid="B41">Simpson and Oliver, 2020</xref>). Therefore, inhibition of ROS-generation might also reduce proinflammatory parameters such as PGE<sub>2</sub>. Since 8-iso-PGF<sub>2&#x3b1;</sub>-synthesis is independent of COX enzymatic activity and protein levels, AM404 might reduce IL-1&#x3b2;-induced PGE<sub>2</sub>-levels without affecting COX-2 enzyme activity, protein, or mRNA levels (<xref ref-type="bibr" rid="B48">Watkins et&#x20;al., 1999</xref>). Therefore, PGE<sub>2</sub>-levels might be decreased AM404-dependently <italic>via</italic> ROS and 8-iso-PGF<sub>2&#x3b1;</sub> pathways (<xref ref-type="bibr" rid="B46">Ting and Khasawneh, 2010</xref>; <xref ref-type="bibr" rid="B1">Acquaviva et&#x20;al., 2013</xref>). However, the role of COX in the production of 8-iso-PGF<sub>2&#x3b1;</sub> is discussed controversially, with some authors suggesting an COX enzyme-dependent generation of isoprostanes (<xref ref-type="bibr" rid="B5">Bauer et&#x20;al., 2014</xref>). Nevertheless, COX-2 activity is associated with much higher concentrations of PGF<sub>2&#x3b1;</sub> instead of 8-iso-PGF<sub>2&#x3b1;</sub> (<xref ref-type="bibr" rid="B47">van &#x2019;t Erve et&#x20;al., 2015</xref>), thus, regulation of 8-iso-PGF<sub>2&#x3b1;</sub>-levels seems to be COX-2 independent. Further research is necessary to fully understand the role of 8-iso-PGF<sub>2&#x3b1;</sub> as potentially signaling molecule in the COX-2/PGE<sub>2</sub> pathway.</p>
<p>Since the role of COX-2 remains discussed controversially (<xref ref-type="bibr" rid="B23">Kopschina Feltes et&#x20;al., 2017</xref>) and may not only exert pro-inflammatory but neuroprotective effects in special constellations as well, the lack of effects of acetaminophen and its metabolite AM404 on COX enzymatic activity and protein levels might be beneficial for therapeutic use. The expression of mPGES-1, the enzyme converting PGH<sub>2</sub> to PGE<sub>2</sub>, is reliably induced by IL-1&#x3b2; in SK-N-SH-cells. As shown for microglia (<xref ref-type="bibr" rid="B39">Saliba et&#x20;al., 2017</xref>), AM404 does not show any concentration-dependent effects on mPGES-1 expression in SK-N-SH-cells, although it shows a significant increase of mPGES-1 mRNA levels at concentrations of 1&#xa0;&#xb5;M. Unfortunately, SK-N-SH cells show high levels of basal mPGES-1 immunoreactivity with only minor induction by IL-1&#x3b2;. This might be due to non-specific binding of the antibody used to other constitutive PGES isoforms such as cPGES or mPGES-2. Hence, this important final step of the COX-2/PGE<sub>2</sub> pathway cannot be examined on the protein level in SK-N-SH-cells.</p>
<p>Another possible mechanism to explain the decrease of PGE<sub>2</sub>-and 8-iso-PGF<sub>2&#x3b1;</sub>-release might be through intracellular calcium concentrations. Since AA, a necessary substrate in the synthesis of PGE<sub>2</sub> and 8-iso-PGF<sub>2&#x3b1;</sub>, is mobilized calcium-dependent by cytosolic phospholipase A<sub>2</sub> (<xref ref-type="bibr" rid="B25">Leslie, 2015</xref>), decreasing intracellular calcium concentrations may lead to reduced PGE<sub>2</sub>-and 8-iso-PGF<sub>2&#x3b1;</sub>-synthesis due to lack of substrate. We and others have demonstrated that AM404 decreased intracellular calcium responses (<xref ref-type="bibr" rid="B3">Alptekin et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B22">Kerckhove et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B38">Saliba et&#x20;al., 2019</xref>) and therefore AM404 might reduce in consequence of decreased intracellular calcium levels the mobilization of AA as substrate for PGE<sub>2</sub>-and 8-iso-PGF<sub>2&#x3b1;</sub>-synthesis.</p>
<p>One other possible mechanism how AM404 is affecting PGE<sub>2</sub>-levels might be an interaction with the peroxidation site of COX-2, which has also been proposed for acetaminophen and ascorbic acid (<xref ref-type="bibr" rid="B16">Fiebich et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B9">Boutaud et&#x20;al., 2002</xref>; <xref ref-type="bibr" rid="B12">Candelario-Jalil et&#x20;al., 2006</xref>).</p>
<p>AM404 is suggested to enfold its central effects <italic>via</italic> CB1 or TRPV1 (<xref ref-type="bibr" rid="B51">Zygmunt et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B6">Bertolini et&#x20;al., 2006</xref>). Our results, however, suggest a CB1- and TRPV-1 independent decrease of PGE<sub>2</sub>-levels in SK-N-SH-cells, since CB1 receptor agonists, such as ACEA, are associated with increased PGE<sub>2</sub>-concentrations as also confirmed by others (<xref ref-type="bibr" rid="B29">Mitchell, 1993</xref>). CB2 agonists, such as JWH-015, indeed are reducing PGE<sub>2</sub>-release (<xref ref-type="bibr" rid="B50">Zoppi et&#x20;al., 2014</xref>), but we found that JWH-015 only reduced IL-1&#x3b2;-induced PGE<sub>2</sub>-levels maximal 50% in the high dose of 10&#xa0;&#xb5;M. Therefore, CB2 agonism does not explain the strong reduction of PGE<sub>2</sub>-levels by AM404. Furthermore, the concentrations of AM404 necessary to bind and activate CB2 receptors are much higher compared to ACEA or JWH-015 (CB1: Ki ACEA 1.4&#xa0;nM; Ki JWH-015 383&#xa0;nM; Ki AM404 1.5&#xa0;&#x3bc;M; CB2: Ki ACEA 3.1&#xa0;&#x3bc;M; Ki JWH-105 13.8&#xa0;nM; Ki AM404 1.3&#xa0;&#xb5;M) (<xref ref-type="bibr" rid="B4">An et&#x20;al., 2020</xref>). In primary mouse microglia isolated from TRPV-1 knockout mice, the decreasing effects of AM404 on PGE<sub>2</sub> are not affected suggesting also in SK-N-SH-cells an TRPV-1 independent mechanism (<xref ref-type="bibr" rid="B39">Saliba et&#x20;al., 2017</xref>). Therefore, we conclude that the observed PGE<sub>2</sub> inhibiting effects of AM404 are not mediated by CB1 and TRPV1. A partially effect of CB2 agonism is not very likely but cannot be excluded.</p>
<p>As neuroinflammatory and oxidative processes may extensively be involved in neurological and psychiatric diseases such as PD and AD, and depression (<xref ref-type="bibr" rid="B8">Bouayed et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B30">Najjar et&#x20;al., 2013</xref>), targeting these processes opens new therapeutical approaches to these diseases. Clinical studies indicate that pro-inflammatory markers, such as PGE<sub>2</sub>, are frequently and prolonged elevated in patients with major depression (<xref ref-type="bibr" rid="B28">Miller et&#x20;al., 2009</xref>). The depressive-like behavior occurring in rats after overexpression of the COX-2/PGE<sub>2</sub> pathway in hippocampi and being reversed by COX-2 inhibition underlines the hypothesized involvement of PGE<sub>2</sub> in neuropsychiatric diseases (<xref ref-type="bibr" rid="B44">Song et&#x20;al., 2018</xref>).</p>
<p>Biomarkers for lipid peroxidation such as 8-iso-PGF<sub>2&#x3b1;</sub> are found in higher concentrations in psychiatric (<xref ref-type="bibr" rid="B21">Joshi and Pratic&#xf2;, 2014</xref>) and neurodegenerative diseases (<xref ref-type="bibr" rid="B45">Sultana et&#x20;al., 2013</xref>). The shown reduction of IL-1&#x3b2;-induced 8-iso-PGF<sub>2&#x3b1;</sub>-levels due to AM404 and acetaminophen pretreatment of SK-N-SH-cells might therefore be beneficial in the therapy of oxidative stress related neuropsychiatric diseases. Furthermore, AM404 shows half of Trolox&#x2019;s anti-oxidative capacity in the ORAC-assay, underlining momentous anti-oxidative properties of AM404. Therefore, future research elucidating the role of 8-iso-PGF<sub>2&#x3b1;</sub> in inflammatory signaling processes as well as studying the effects of AM404 in animal models of psychiatric or neurodegenerative disorders might revolutionize future therapies. As immune therapies gain more relevance in the treatment of neuropsychiatric diseases (<xref ref-type="bibr" rid="B30">Najjar et&#x20;al., 2013</xref>), acetaminophen might be an alternative as well-established drug with only mild side effects compared to corticosteroids or immunosuppressive&#x20;drugs.</p>
<p>However, the connection between neuroinflammation and oxidative stress is complex and therefore a separated view of both components might be to simplifying. Understanding the interactions between the involved players and the initiator of clinical observed symptoms might lead to an individualization of treatment by using biomarkers of neuroinflammation and oxidative stress to choose and monitor therapies of neurological and psychiatric diseases, for instance.</p>
</sec>
<sec sec-type="conclusion" id="s5">
<title>Conclusion</title>
<p>Many studies have been performed to elucidate the mechanisms of action of acetaminophen and to better understand its effects in different cell types. We show here, that the active acetaminophen metabolite AM404 as well as acetaminophen show significant anti-neuroinflammatory effects by potently inhibiting IL-1&#x3b2;-induced PGE<sub>2</sub>-release in human SK-N-SH-cells. These effects might be mediated by 8-iso-PGF<sub>2&#x3b1;</sub>-reduction as observed for both, AM404 and acetaminophen. Further understanding of the role of AM404 and acetaminophen in neuroinflammation might revolutionize the use of acetaminophen besides its common application in pain and fever and might lead to future treatment of different psychiatric and neurological disorders with a neuroinflammatory background.</p>
</sec>
</body>
<back>
<sec id="s6">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>BF, SS, MA, JS, and JD participated in research design. The experiments were performed by MA, JS, SS, and JD. Data were analysed by MA, JS, and SS. MA, JS, SS, EM, and BF wrote or contributed to the writing of the manuscript. In addition, MA, JS, SS, EM, and BF reviewed the data and discussed the manuscript. All authors have read and approved the final version of the manuscript.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and the University of Freiburg Library in the funding program &#xab; Open Access Publishing &#xbb;.</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ack>
<p>The skillful technical assistance of Ulrike G&#xf6;tzinger-Berger and Brigitte G&#xfc;nter in cell culture and EIA is greatly acknowledged. The authors thank the University of Freiburg Library for their support <italic>via</italic> the funding program &#xab; Open Access Publishing &#xbb;.</p>
</ack>
<sec id="s11">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2021.789074/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2021.789074/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image1.JPEG" id="SM1" mimetype="application/JPEG" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Image2.pdf" id="SM2" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Acquaviva</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vecchio</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arezzini</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Comporti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gardi</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Signaling Pathways Involved in Isoprostane-Mediated Fibrogenic Effects in Rat Hepatic Stellate Cells</article-title>. <source>Free Radic. Biol. Med.</source> <volume>65</volume>, <fpage>201</fpage>&#x2013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2013.06.023</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamczyk</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Go&#x142;da</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McCreary</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Przegali&#x144;ski</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Activation of Endocannabinoid Transmission Induces Antidepressant-like Effects in Rats</article-title>. <source>J.&#x20;Physiol. Pharmacol.</source> <volume>59</volume>, <fpage>217</fpage>&#x2013;<lpage>228</lpage>. </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alptekin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Galadari</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shuba</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Petroianu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Oz</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The Effects of Anandamide Transport Inhibitor AM404 on Voltage-dependent Calcium Channels</article-title>. <source>Eur. J.&#x20;Pharmacol.</source> <volume>634</volume>, <fpage>10</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2010.02.013</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Peigneur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hendrickx</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Tytgat</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products</article-title>. <source>Int. J.&#x20;Mol. Sci.</source> <volume>21</volume>, <fpage>E5064</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21145064</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ripperger</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Frantz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Erg&#xfc;n</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schwedhelm</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Benndorf</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Pathophysiology of Isoprostanes in the Cardiovascular System: Implications of Isoprostane-Mediated Thromboxane A2 Receptor Activation</article-title>. <source>Br. J.&#x20;Pharmacol.</source> <volume>171</volume>, <fpage>3115</fpage>&#x2013;<lpage>3131</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12677</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertolini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ottani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Guerzoni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tacchi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Paracetamol: New Vistas of an Old Drug</article-title>. <source>CNS Drug Rev.</source> <volume>12</volume>, <fpage>250</fpage>&#x2013;<lpage>275</lpage>. <pub-id pub-id-type="doi">10.1111/j.1527-3458.2006.00250.x</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bortolato</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Campolongo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mangieri</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Scattoni</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Frau</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Anxiolytic-Like Properties of the Anandamide Transport Inhibitor AM404</article-title>. <source>Neuropsychopharmacology</source> <volume>31</volume>, <fpage>2652</fpage>&#x2013;<lpage>2659</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1301061</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouayed</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rammal</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Soulimani</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Oxidative Stress and Anxiety: Relationship and Cellular Pathways</article-title>. <source>Oxid. Med. Cel Longev.</source> <volume>2</volume>, <fpage>63</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.4161/oxim.2.2.7944</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boutaud</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Aronoff</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Marnett</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Oates</surname>
<given-names>J.&#x20;A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Determinants of the Cellular Specificity of Acetaminophen as an Inhibitor of Prostaglandin H(2) Synthases</article-title>. <source>Proc. Natl. Acad. Sci. U S A.</source> <volume>99</volume>, <fpage>7130</fpage>&#x2013;<lpage>7135</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.102588199</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brundin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Melki</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kopito</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Prion-like Transmission of Protein Aggregates in Neurodegenerative Diseases</article-title>. <source>Nat. Rev. Mol. Cel Biol.</source> <volume>11</volume>, <fpage>301</fpage>&#x2013;<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2873</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caballero</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Navarrete</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fiebich</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Appendino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Macho</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>The Acetaminophen-Derived Bioactive N-Acylphenolamine AM404 Inhibits NFAT by Targeting Nuclear Regulatory Events</article-title>. <source>Biochem. Pharmacol.</source> <volume>73</volume>, <fpage>1013</fpage>&#x2013;<lpage>1023</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2006.12.001</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Candelario-Jalil</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Akundi</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Bhatia</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Lieb</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Appel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mu&#xf1;oz</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Ascorbic Acid Enhances the Inhibitory Effect of Aspirin on Neuronal Cyclooxygenase-2-Mediated Prostaglandin E2 Production</article-title>. <source>J.&#x20;Neuroimmunol.</source> <volume>174</volume>, <fpage>39</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2006.01.003</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Craft</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>Watterson</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Van Eldik</surname>
<given-names>L. J.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Neuroinflammation: a Potential Therapeutic Target</article-title>. <source>Expert Opin. Ther. Targets</source> <volume>9</volume>, <fpage>887</fpage>&#x2013;<lpage>900</lpage>. <pub-id pub-id-type="doi">10.1517/14728222.9.5.887</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Espejo</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Caraballo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rodriguez de Fonseca</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>El Banoua</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Flores</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Experimental Parkinsonism Alters Anandamide Precursor Synthesis, and Functional Deficits Are Improved by AM404: A Modulator of Endocannabinoid Function</article-title>. <source>Neuropsychopharmacology</source> <volume>29</volume>, <fpage>1134</fpage>&#x2013;<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300407</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiebich</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Chrubasik</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Effects of an Ethanolic Salix Extract on the Release of Selected Inflammatory Mediators <italic>In Vitro</italic>
</article-title>. <source>Phytomedicine</source> <volume>11</volume>, <fpage>135</fpage>&#x2013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1078/0944-7113-00338</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fiebich</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Lieb</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>H&#xfc;ll</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aicher</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>van Ryn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pairet</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2000</year>). <article-title>Effects of Caffeine and Paracetamol Alone or in Combination with Acetylsalicylic Acid on Prostaglandin E(2) Synthesis in Rat Microglial Cells</article-title>. <source>Neuropharmacology</source> <volume>39</volume>, <fpage>2205</fpage>&#x2013;<lpage>2213</lpage>. <pub-id pub-id-type="doi">10.1016/S0028-3908(00)00045-9</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flower</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Vane</surname>
<given-names>J.&#x20;R.</given-names>
</name>
</person-group> (<year>1972</year>). <article-title>Inhibition of Prostaglandin Synthetase in Brain Explains the Anti-pyretic Activity of Paracetamol (4-Acetamidophenol)</article-title>. <source>Nature</source> <volume>240</volume>, <fpage>410</fpage>&#x2013;<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1038/240410a0</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garc&#xed;a-Arencibia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gonz&#xe1;lez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>de Lago</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<name>
<surname>Mechoulam</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fern&#xe1;ndez-Ruiz</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Evaluation of the Neuroprotective Effect of Cannabinoids in a Rat Model of Parkinson&#x27;s Disease: Importance of Antioxidant and Cannabinoid Receptor-independent Properties</article-title>. <source>Brain Res.</source> <volume>1134</volume>, <fpage>162</fpage>&#x2013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2006.11.063</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>H&#xf6;gest&#xe4;tt</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>J&#xf6;nsson</surname>
<given-names>B. A. G.</given-names>
</name>
<name>
<surname>Ermund</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Bj&#xf6;rk</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>J.&#x20;P.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Conversion of Acetaminophen to the Bioactive N-Acylphenolamine AM404&#x20;<italic>via</italic> Fatty Acid Amide Hydrolase-dependent Arachidonic Acid Conjugation in the Nervous System</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>280</volume>, <fpage>31405</fpage>&#x2013;<lpage>31412</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M501489200</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Lee-Chen</surname>
<given-names>G. J.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Chronic Low Dose of AM404 Ameliorates the Cognitive Impairment and Pathological Features in Hyperglycemic 3xTg-AD Mice</article-title>. <source>Psychopharmacology (Berl)</source> <volume>236</volume>, <fpage>763</fpage>&#x2013;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-018-5108-0</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joshi</surname>
<given-names>Y. B.</given-names>
</name>
<name>
<surname>Pratic&#xf2;</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Lipid Peroxidation in Psychiatric Illness: Overview of Clinical Evidence</article-title>. <source>Oxid. Med. Cel Longev.</source> <volume>2014</volume>, <fpage>828702</fpage>. <pub-id pub-id-type="doi">10.1155/2014/828702</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kerckhove</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fran&#xe7;ois</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Boudes</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chemin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Voets</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Ca(v)3.2 Calcium Channels: the Key Protagonist in the Supraspinal Effect of Paracetamol</article-title>. <source>Pain</source> <volume>155</volume>, <fpage>764</fpage>&#x2013;<lpage>772</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2014.01.015</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kopschina Feltes</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Doorduin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Ju&#xe1;rez-Orozco</surname>
<given-names>L. E.</given-names>
</name>
<name>
<surname>Dierckx</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Moriguchi-Jeckel</surname>
<given-names>C. M.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Anti-inflammatory Treatment for Major Depressive Disorder: Implications for Patients with an Elevated Immune Profile and Non-responders to Standard Antidepressant Therapy</article-title>. <source>J.&#x20;Psychopharmacol.</source> <volume>31</volume>, <fpage>1149</fpage>&#x2013;<lpage>1165</lpage>. <pub-id pub-id-type="doi">10.1177/0269881117711708</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Prostaglandin E Synthase, a Terminal Enzyme for Prostaglandin E Biosynthesis</article-title>. <source>BMB Reports.</source> <volume>38</volume>, <fpage>633</fpage>&#x2013;<lpage>638</lpage>. <pub-id pub-id-type="doi">10.5483/BMBRep.2005.38.6.633</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Trott</surname>
<given-names>J.&#x20;S.</given-names>
</name>
<name>
<surname>Haque</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>McCormick</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chiorazzi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mongini</surname>
<given-names>P. K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>A Cyclooxygenase-2/prostaglandin E2 Pathway Augments Activation-Induced Cytosine Deaminase Expression within Replicating Human B&#x20;Cells</article-title>. <source>J.&#x20;Immunol.</source> <volume>185</volume>, <fpage>5300</fpage>&#x2013;<lpage>5314</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1000574</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leslie</surname>
<given-names>C. C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Cytosolic Phospholipase A&#x2082;: Physiological Function and Role in Disease</article-title>. <source>J.&#x20;Lipid Res.</source> <volume>56</volume>, <fpage>1386</fpage>&#x2013;<lpage>1402</lpage>. <pub-id pub-id-type="doi">10.1194/jlr.R057588</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lima</surname>
<given-names>I. V. d. A.</given-names>
</name>
<name>
<surname>Bastos</surname>
<given-names>L. F. S.</given-names>
</name>
<name>
<surname>Limbor&#xe7;o-Filho</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fiebich</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>A. C. P.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Role of Prostaglandins in Neuroinflammatory and Neurodegenerative Diseases</article-title>. <source>Mediators Inflamm.</source> <volume>2012</volume>, <fpage>1</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1155/2012/946813</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mark</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Fuson</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>May</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Characterization of 8-Epiprostaglandin F2&#x3b1; as aMarker of Amyloid &#x3b2;-Peptide-Induced Oxidative Damage</article-title>. <source>J.&#x20;Neurochem.</source> <volume>72</volume>, <fpage>1146</fpage>&#x2013;<lpage>1153</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0721146.x</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Maletic</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Raison</surname>
<given-names>C. L.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Inflammation and its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression</article-title>. <source>Biol. Psychiatry</source> <volume>65</volume>, <fpage>732</fpage>&#x2013;<lpage>741</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.11.029</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Situational Interest: Its Multifaceted Structure in the Secondary School Mathematics Classroom</article-title>. <source>J.&#x20;Educ. Psychol.</source> <volume>85</volume>, <fpage>424</fpage>&#x2013;<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1037/0022-0663.85.3.424</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Najjar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pearlman</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Alper</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Najjar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Neuroinflammation and Psychiatric Illness</article-title>. <source>J.&#x20;Neuroinflammation</source> <volume>10</volume>, <fpage>43</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-10-43</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naz&#x131;ro&#x11f;lu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Taner</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Balbay</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>&#xc7;i&#x11f;</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Inhibitions of Anandamide Transport and FAAH Synthesis Decrease Apoptosis and Oxidative Stress through Inhibition of TRPV1 Channel in an <italic>In Vitro</italic> Seizure Model</article-title>. <source>Mol. Cel Biochem.</source> <volume>453</volume>, <fpage>143</fpage>&#x2013;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1007/s11010-018-3439-0</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohashi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kohno</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Analgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action</article-title>. <source>Front. Pharmacol.</source> <volume>11</volume>, <fpage>580289</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2020.580289</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pacher</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>B&#xe1;tkai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kunos</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>The Endocannabinoid System as an Emerging Target of Pharmacotherapy</article-title>. <source>Pharmacol. Rev.</source> <volume>58</volume>, <fpage>389</fpage>&#x2013;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1124/pr.58.3.2</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Pharmacological Evaluation of Cannabinoid Receptor Ligands in a Mouse Model of Anxiety: Further Evidence for an Anxiolytic Role for Endogenous Cannabinoid Signaling</article-title>. <source>J.&#x20;Pharmacol. Exp. Ther.</source> <volume>318</volume>, <fpage>304</fpage>&#x2013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.106.101287</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picca</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Calvani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Coelho-Junior</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Landi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bernabei</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Marzetti</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration</article-title>. <source>Antioxidants (Basel)</source> <volume>9</volume>, <fpage>647</fpage>. <pub-id pub-id-type="doi">10.3390/antiox9080647</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roche</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>J.&#x20;P.</given-names>
</name>
<name>
<surname>O&#x27;Driscoll</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>D. P.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Augmentation of Endogenous Cannabinoid Tone Modulates Lipopolysaccharide-Induced Alterations in Circulating Cytokine Levels in Rats</article-title>. <source>Immunology</source> <volume>125</volume>, <fpage>263</fpage>&#x2013;<lpage>271</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.02838.x</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rozp&#x119;dek-Kami&#x144;ska</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Siwecka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wawrzynkiewicz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wojtczak</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pytel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>J.&#x20;A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The PERK-dependent Molecular Mechanisms as a Novel Therapeutic Target for Neurodegenerative Diseases</article-title>. <source>Int. J.&#x20;Mol. Sci.</source> <volume>21</volume>, <fpage>2108</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21062108</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saliba</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Bonifacino</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Serchov</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bonanno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>A. C. P.</given-names>
</name>
<name>
<surname>Fiebich</surname>
<given-names>B. L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Neuroprotective Effect of AM404 against NMDA-Induced Hippocampal Excitotoxicity</article-title>. <source>Front Cel Neurosci.</source> <volume>13</volume>, <fpage>566</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2019.00566</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saliba</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Marcotegui</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Fortw&#xe4;ngler</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ditrich</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Perazzo</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Mu&#xf1;oz</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>AM404, Paracetamol Metabolite, Prevents Prostaglandin Synthesis in Activated Microglia by Inhibiting COX Activity</article-title>. <source>J.&#x20;Neuroinflammation</source> <volume>14</volume>, <fpage>246</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-017-1014-3</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samuelsson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Granstrom</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hamberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hammarstrom</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1975</year>). <article-title>Prostaglandins</article-title>. <source>Annu. Rev. Biochem.</source> <volume>44</volume>, <fpage>669</fpage>&#x2013;<lpage>695</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.bi.44.070175.003321</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salim</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Oxidative Stress and Psychological Disorders</article-title>. <source>Curr. Neuropharmacol.</source> <volume>12</volume>, <fpage>140</fpage>&#x2013;<lpage>147</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X11666131120230309</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sigal</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>The Molecular Biology of Mammalian Arachidonic Acid Metabolism</article-title>. <source>Am. J. Physiol. Lung Cell Mol.</source> <volume>260</volume>, <fpage>L13</fpage>&#x2013;<lpage>L28</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.1991.260.2.L13</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simpson</surname>
<given-names>D. S. A.</given-names>
</name>
<name>
<surname>Oliver</surname>
<given-names>P. L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease</article-title>. <source>Antioxidants (Basel)</source> <volume>9</volume>, <fpage>743</fpage>. <pub-id pub-id-type="doi">10.3390/antiox9080743</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kukreti</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Saso</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kukreti</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Oxidative Stress: A Key Modulator in Neurodegenerative Diseases</article-title>. <source>Molecules</source> <volume>24</volume>, <fpage>1583</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24081583</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solleiro-Villavicencio</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rivas-Arancibia</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Effect of Chronic Oxidative Stress on Neuroinflammatory Response Mediated by CD4&#x2b;T&#x20;Cells in Neurodegenerative Diseases</article-title>. <source>Front. Cel. Neurosci.</source> <volume>12</volume>, <fpage>114</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2018.00114</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Hippocampal CA1 &#x3b2;CaMKII Mediates Neuroinflammatory Responses <italic>via</italic> COX-2/PGE2 Signaling Pathways in Depression</article-title>. <source>J.&#x20;Neuroinflammation</source> <volume>15</volume>, <fpage>338</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-018-1377-0</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sultana</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Perluigi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Lipid Peroxidation Triggers Neurodegeneration: a Redox Proteomics View into the Alzheimer Disease Brain</article-title>. <source>Free Radic. Biol. Med.</source> <volume>62</volume>, <fpage>157</fpage>&#x2013;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.09.027</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ting</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Khasawneh</surname>
<given-names>F. T.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Platelet Function and Isoprostane Biology. Should Isoprostanes Be the Newest Member of the Orphan-Ligand Family?</article-title> <source>J.&#x20;Biomed. Sci.</source> <volume>17</volume>, <fpage>24</fpage>. <pub-id pub-id-type="doi">10.1186/1423-0127-17-24</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van &#x27;t Erve</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Lih</surname>
<given-names>F. B.</given-names>
</name>
<name>
<surname>Kadiiska</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Deterding</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Eling</surname>
<given-names>T. E.</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>R. P.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Reinterpreting the Best Biomarker of Oxidative Stress: The 8-iso-PGF(2&#x3b1;)/PGF(2&#x3b1;) Ratio Distinguishes Chemical from Enzymatic Lipid Peroxidation</article-title>. <source>Free Radic. Biol. Med.</source> <volume>83</volume>, <fpage>245</fpage>&#x2013;<lpage>251</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.03.004</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watkins</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Patton</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Soler</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Albadawi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Humphries</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>J.&#x20;E.</given-names>
</name>
<etal/>
</person-group> (<year>1999</year>). <article-title>Synthesis of 8-Epi-Prostaglandin F2alpha by Human Endothelial Cells: Role of Prostaglandin H2 Synthase</article-title>. <source>Biochem. J.</source> <volume>344</volume>, <fpage>747</fpage>&#x2013;<lpage>754</lpage>. <pub-id pub-id-type="doi">10.1042/bj3440747</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yap</surname>
<given-names>J.&#x20;K. Y.</given-names>
</name>
<name>
<surname>Pickard</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>E. W. L.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Role of Neuronal NLRP1 Inflammasome in Alzheimer&#x27;s Disease: Bringing Neurons into the Neuroinflammation Game</article-title>. <source>Mol. Neurobiol.</source> <volume>56</volume>, <fpage>7741</fpage>&#x2013;<lpage>7753</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-019-1638-7</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zoppi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Madrigal</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Caso</surname>
<given-names>J.&#x20;R.</given-names>
</name>
<name>
<surname>Garc&#xed;a-Guti&#xe9;rrez</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Manzanares</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Leza</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Regulatory Role of the Cannabinoid CB2 Receptor in Stress-Induced Neuroinflammation in Mice</article-title>. <source>Br. J.&#x20;Pharmacol.</source> <volume>171</volume>, <fpage>2814</fpage>&#x2013;<lpage>2826</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12607</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zygmunt</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Movahed</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Julius</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>H&#xf6;gest&#xe4;tt</surname>
<given-names>E. D.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>The Anandamide Transport Inhibitor AM404 Activates Vanilloid Receptors</article-title>. <source>Eur. J.&#x20;Pharmacol.</source> <volume>396</volume>, <fpage>39</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(00)00207-7</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>